Case report: identification of fusion in a patient with pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. Currently, treatment strategies for PDAC are limited because its molecular characteristics have not yet been clarified. Different fusions have been reported in diverse solid tumors, especially in non-small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC). Multikinase inhibitors (MKIs) such as cabozantinib, vandetanib and lenvatinib, as well as selective inhibitors of alterations like selpercatinib (LOXO-292) and pralsetinib (BLU-667) have been approved by the Food and Drug Administration (FDA) for patients with fusion-positive tumors, such as thyroid cancer, renal cell, NSCLC, and so on. However, few studies have been reported about the association between fusions and PDAC. fusion is a rare rearrangement. To date, it has only been reported in lung cancer and thyroid cancer. Studies of fusion in PDAC have not yet been explored. In this study, we reported an fusion in a 60-year-old female patient with PDAC. To the best of our knowledge, this case was the first report about fusion in a patient with PDAC. It is a pity that the patient refused targeted therapy for personal reasons. Our study has shed a new light on the companion diagnostics and targeted therapy for the patients with PDAC.